RayKnowChina Research Map
Shortlist

RecruitingGliomaN/A

Registered title, quoted from ClinicalTrials.gov

A Novel Target Delineation Scheme in High-grade Glioma Patients: a Randomized Single-blind Clinical Trial

An open trial on glioma, registered on ClinicalTrials.gov. Led by Zhujiang Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorZhujiang Hospital南方医科大学珠江医院GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06215495, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 65 years; sex: all

    Registered eligibility fields

  2. Radiotherapy within 4-6 weeks after surgery

    Inclusion criterion 8

    Pregnancy or lactation, or pregnancy or childbirth during the expected trial period(from pre-screening or screening visits until 120 days after the last trial treatment)

    Exclusion criterion 6

  3. Age between 18-65 years old, Karnofsky performance status (KPS) score ≥ 70

    Inclusion criterion 2

  4. result of pregnancy test being negative within 7 days before enrollment, only applicable to women with reproductive potential

    Inclusion criterion 3

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06215495, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • High-grade glioma (2021 WHO grade III or IV)
  • Age between 18-65 years old, Karnofsky performance status (KPS) score ≥ 70
  • result of pregnancy test being negative within 7 days before enrollment, only applicable to women with reproductive potential
  • The patient voluntarily joined this study and signed an informed consent form
  • Willing to return for follow-up
  • Willing to provide tissue and blood samples for this research
  • Surgical treatment was completed without any postoperative complications (such as consciousness disorders, hematomas, lung infection and cardiac insufficiency)
  • Radiotherapy within 4-6 weeks after surgery
  • No contraindications for taking temozolomide

Exclusion Criteria:

  • Low-grade glioma(2021 WHO grade I or II)
  • had or having other type of malignant cancers
  • not having been performed gross total resection of tumor
  • Severe active comorbidities, systemic diseases or other serious comorbidities that would render the patient unsuitable for participation in this study or seriously interfere with the appropriate evaluation of the safety and toxicity of the prescribed regimen in the judgment of the investigator, including but not limited to persistent or active infections, symptomatic congestive heart failure, unstable angina pectoris, arrhythmia, or mental illness;
  • Baseline MRI indicates a previous or recent risk of cerebral hemorrhage or hernia;
  • Pregnancy or lactation, or pregnancy or childbirth during the expected trial period(from pre-screening or screening visits until 120 days after the last trial treatment)
  • Unable to perform brain magnetic resonance imaging;
  • Allergic to CT contrast agent, unable to perform enhanced CT examination;
  • Remote transfer;
  • Medical contraindications for receiving radiation therapy, such as active systemic lupus or scleroderma

Quoted from ClinicalTrials.gov, NCT06215495, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06215495, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06215495